Sight Sciences Q4 2021 Earnings Report
Key Takeaways
Sight Sciences reported a strong fourth quarter and full year 2021, with significant revenue growth and gross margin expansion. The company achieved FDA clearances for OMNI and TearCare, made progress in clinical trials, and advanced R&D efforts.
Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period.
Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period.
Received FDA 510(k) Clearance of the TearCareĀ® System for treatment of Meibomian Gland Disease (MGD).
Completed the largest medical technology IPO of 2021, raising $276 million.
Sight Sciences
Sight Sciences
Sight Sciences Revenue by Segment
Forward Guidance
Sight Sciences projects revenue for the full year 2022 to range from $67 million to $75 million, which represents approximately 45% growth compared to 2021 using the midpoint of the range.
Revenue & Expenses
Visualization of income flow from segment revenue to net income